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671Abstracts
OBJECTIVE: All chemotherapy regimens are associated with
some degree of adverse events. The more severe adverse events
require hospitalization and may be associated with high costs.
One adverse event that may be serious is infection and in par-
ticular infection because of neutropenia. The objective of this
study was to retrospectively assess the hospitalization costs of
infections and neutropenia in cancer patients. METHODS: Indi-
vidual patient data on costs, diagnoses, and length of stay were
collected from the largest cost per patient inpatient database in
Sweden. The time period was January 1999 to January 2000.
The hospitals included in the database all have a detailed
resource tracking and cost assignment system for determining the
individual cost per stay. All non-surgical patients who had the
combination of a cancer ICD-10 (C000 to C997) and an infec-
tion diagnosis recorded in the database were selected. Patients
who also had a neutropenia (D709) diagnosis recorded were
selected and studied as a subsample of the whole sample.
RESULTS: There were 2378 patients who had a cancer and an
infection diagnosis. Their mean cost was (SEK) 69,700 and the
mean length of stay was 12.3 days. The average age was 62 years
and there were 59% women. Patients with a principal cancer
diagnosis had greater costs than patients with a secondary cancer
diagnosis, 85,500 versus 50,600. Out of the 2378 patients there
were 52 who had both neutropenia and an infection. Their mean
age was 55 years. There were slightly more women than men,
54%. The mean cost was (SEK) 77,900 and the mean length of
stay was 12.9 days. CONCLUSIONS: The hospitalization costs
of infections and neutropenia in cancer patients are signiﬁcant.
When assessing the costs of chemotherapy treatments, not only
pharmaceutical costs, but also costs of adverse events should be
included.
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OBJECTIVES: The objective of this study was to determine the
lifetime cost of treating NSCLC patients with geﬁtinib. NSCLC
is a fatal malignancy that responds poorly to chemotherapy. Best
Supportive Care (BSC) is frequently offered when management
with anticancer treatments is not feasible. Geﬁtinib (“Iressa”) is
the ﬁrst epidermal growth factor receptor tyrosine kinase
inhibitor approved for the treatment of patients with locally
advanced or metastatic NSCLC. METHODS: Duration of geﬁ-
tinib treatment was estimated by the time to progression in
IDEAL 2, a phase II clinical trial involving patients with
advanced or metastatic NSCLC who had previously received
platinum-based chemotherapy. Post progression, patients were
assumed to receive BSC. Resource utilization was estimated from
the clinical trial. The cost of BSC following chemotherapy was
provided by CancerCare Manitoba. Costs were expressed in
Canadian dollars (2003). RESULTS: Patients (n = 102) received
geﬁtinib 250mg daily. Over 40% of patients achieved a complete
response, partial response or stable disease, and clinically signif-
icant improvement in disease-related symptoms occurred in most
of these patients. Median time to progression was 1.9 months.
The median survival time was 7 months. The tolerability proﬁle
of geﬁtinib was mild and there was a low incidence of grade 3/4
adverse reactions. The lifetime cost of treating a patient with geﬁ-
tinib plus BSC was estimated at $14,496. In sensitivity analyses,
that lifetime cost ranged from $13,822 up to $24,915. CONL-
CUSIONS: The lifetime cost to treat a patient with geﬁtinib plus
BSC was $14,496, which is comparable to costs for other
chemotherapies for NSCLC. For example, the lifetime cost of
second-line docetaxel was $17,739 (1999 dollars [$19,389 in
2003 dollars]) and for other chemotherapies, lifetime costs
ranged from $24,828 up to $41,178 (1995 dollars [$29,059 to
$48,196 in 2003 dollars]). “Iressa” is a trademark of the
AstraZeneca group of companies.
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OBJECTIVES: Oral ibandronate (ibandronic acid) is a bisphos-
phonate approved in the UK for treatment of bone metastases
from breast cancer. Administration of oral ibandronate once-
daily can be easily combined with oral hormonal therapy, saving
costs of iv bisphosphonate administration and monitoring. We
used cost-effectiveness (C/E) modelling to compare oral iban-
dronate with iv zoledronic acid or iv generic pamidronate in this
setting. METHODS: The model assumed a UK NHS perspective
with a duration of 14.3 months (expected average survival).
Patients were assumed to receive oral hormonal therapy for 53%
of their survival. Primary outcomes were direct Health Care costs
and QALYs. Resource use data for iv bisphosphonates came
from a published micro-costing study (validated through review
by a UK clinician); costs were calculated using a unit cost data-
base. Monthly drug acquisition costs were £195 for oral iban-
dronate and iv zoledronic acid, and £165 for iv generic
pamidronate. The cost of managing skeletal-related events
(SREs) came from a published study. Renal adverse events with
monitoring and treatment costs were assumed for zoledonic acid.
Efﬁcacy was calculated as the relative risk reduction (RR) of
SREs; utility scores were applied to time with/without an SRE
(SRE duration assumed 1 month). RESULTS: The projected total
cost was £297 less/patient with oral ibandronate than with zole-
dronic acid, and £1087 less than with generic pamidronate. Oral
ibandronate led to a gain of 0.02 QALYs (due to SRE RR and
bone pain relief), making it the economically dominant treatment
option. For completeness, C/E results for iv ibandronate will also
be presented, demonstrating C/E. CONCLUSIONS: This study
demonstrated the use of C/E modelling to compare oral versus
iv bisphosphonates using published data validated by expert clin-
ician review. Oral ibandronate was found to be cost-effective for
the management of bone metastases from breast cancer in
patients receiving oral hormonal therapy.
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OBJECTIVES: Oral bisphosphonates should reduce medical
resource use versus iv infusions. A US study used time-in-motion
methods to assess resource use for iv zoledronic acid vs. iv
pamidronate (DesHarnais CL et al, Support Care Cancer 2001).
